Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

A Double‐Blind, Placebo‐Controlled Study of the Safety, Tolerability and Pharmacokinetics of CP‐101,606 in Patients with a Mild or Moderate Traumatic Brain Injury

A Double‐Blind, Placebo‐Controlled Study of the Safety, Tolerability and Pharmacokinetics of... ABSTRACT: CP‐101,606 is a postsynaptic antagonist of the glutamate‐mediated NR2B subunit of the N‐methyl‐d‐aspartate (NMDA) receptor. When administered intravenously (i.v.) at the time of injury, CP‐101,606 is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia. Minimal adverse effects have been observed in normal human volunteers given i.v. doses of up to 3 mg/kg/hr for 72 hours. The objective of the present clinical trial was to assess the safety, pharmacokinetics, and tolerability of CP‐101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9‐14) or hemorrhagic stroke. Patients began receiving treatment within 12 hours of brain injury. A total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double‐blind fashion to receive CP‐101,606 or placebo (4 drug:1 placebo). Drug/placebo was administered by i.v. infusion (0.75 mg/kg/hr) for 2 hours and then stopped ( n= 25 ) or continued for 22 hours ( n= 4 ) or 70 hours ( n= 24 ) at a rate of 0.37 mg/kg/hr. Mean plasma drug concentrations were well above the predicted therapeutic concentration of 200 ng/ml within two hours of initiating treatment and were sustained as long as drug was infused. All the patients tolerated their drug/placebo treatment, and there were no clinically significant cardiovascular or hematological abnormalities in either group. A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo. Modified Kurtzke Scoring also showed a similar pattern of improvement irrespective of type of head injury or drug/placebo treatment. This study suggests that CP‐101,606, infused for up to 72 hours has no psychotropic effects and is well‐tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of the New York Academy of Sciences Wiley

A Double‐Blind, Placebo‐Controlled Study of the Safety, Tolerability and Pharmacokinetics of CP‐101,606 in Patients with a Mild or Moderate Traumatic Brain Injury

Download PDF
9 pages

Loading next page...
 
/lp/wiley/a-double-blind-placebo-controlled-study-of-the-safety-tolerability-and-QPeOz8FLCN

References (12)

Publisher
Wiley
Copyright
Copyright © 1999 Wiley Subscription Services
ISSN
0077-8923
eISSN
1749-6632
DOI
10.1111/j.1749-6632.1999.tb07979.x
Publisher site
See Article on Publisher Site

Abstract

ABSTRACT: CP‐101,606 is a postsynaptic antagonist of the glutamate‐mediated NR2B subunit of the N‐methyl‐d‐aspartate (NMDA) receptor. When administered intravenously (i.v.) at the time of injury, CP‐101,606 is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia. Minimal adverse effects have been observed in normal human volunteers given i.v. doses of up to 3 mg/kg/hr for 72 hours. The objective of the present clinical trial was to assess the safety, pharmacokinetics, and tolerability of CP‐101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9‐14) or hemorrhagic stroke. Patients began receiving treatment within 12 hours of brain injury. A total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double‐blind fashion to receive CP‐101,606 or placebo (4 drug:1 placebo). Drug/placebo was administered by i.v. infusion (0.75 mg/kg/hr) for 2 hours and then stopped ( n= 25 ) or continued for 22 hours ( n= 4 ) or 70 hours ( n= 24 ) at a rate of 0.37 mg/kg/hr. Mean plasma drug concentrations were well above the predicted therapeutic concentration of 200 ng/ml within two hours of initiating treatment and were sustained as long as drug was infused. All the patients tolerated their drug/placebo treatment, and there were no clinically significant cardiovascular or hematological abnormalities in either group. A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo. Modified Kurtzke Scoring also showed a similar pattern of improvement irrespective of type of head injury or drug/placebo treatment. This study suggests that CP‐101,606, infused for up to 72 hours has no psychotropic effects and is well‐tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.

Journal

Annals of the New York Academy of Sciences – Wiley

Published: Jan 1, 1999

There are no references for this article.